You are here

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Last updated on July 30, 2018

FOR MORE INFORMATION
Study Location
Anaheim Clinical Trials
Anaheim, California, 92801 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Males and female subjects of non-childbearing potential between the ages of 18 and 70
years, inclusive of age at the time of the screening visit.

Female subjects of non-childbearing potential must meet at least one of the following
criteria:

1. Achieved postmenopausal status, defined as: cessation of regular menses for at least
12 consecutive months with no alternative pathological or physiological cause; and
have a serum FSH level within the laboratory's reference range for postmenopausal
females;

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure.

4. All other female subjects (including females with tubal ligations and females that do
NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure)
will be considered to be of childbearing potential.

- Body Mass Index (BMI) of 18.0 to 45.0 kg/m2; and a total body weight >50 kg (110
lbs).

- An informed consent document signed and dated by the subject.

- Subjects who are willing and able to comply with scheduled visits, treatment
plan, laboratory tests, and other study procedures.

PART A ONLY: Subjects treated with metformin monotherapy for at least 3 months at the time
of the screening visit; and have been on a stable dose of metformin for at least 6 weeks
prior to the first dose of study drug on Day 1. Subjects must be taking a minimum total
metformin daily dose of least 1000 mg. Subjects treated with a dipeptidyl peptidase-4
inhibitor (DPP-4i), a sulfonylurea or a sodium-glucose cotransporter-2 inhibitor (SGLT-2i)
in combination with metformin may be eligible if washed off the DPP-4i, sulfonylurea or
SGLT-2i for a minimum of 4 weeks prior to dosing. Subjects being washed off a DPP-4i,
sulfonylurea or SGLT-2i will still need to meet the fasting glucose requirements as defined
in the Inclusion Criteria.

PART B ONLY: Subjects treated with metformin plus a sulfonylurea for at least 3 months at
the time of the screening visit; and have been on a stable dose of metformin and a
sulfonylurea for at least 6 weeks prior to first dose of study drug on Day 1. Subjects must
be taking a minimum total metformin daily dose of least 1000 mg and a total daily dose of
sulfonylurea that is at least the minimum recommended starting dose found in the product
label. Subjects treated with a DPP-4i or SGLT-2i in combination with metformin and a
sulfonylurea may be eligible if washed off the DPP-4i or SGLT-2i for a minimum of 4 weeks
before dosing.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of Type 1 diabetes mellitus or secondary forms of diabetes.

- One or more self-reported hypoglycemic episodes of severe intensity within 3 months of
screening; or two or more self-reported hypoglycemic episodes of severe intensity
within the last 6 months.

- Recent [ie, within six (6) months prior to screening] evidence or medical history of
unstable concurrent disease such as: clinically significant hematological,
endocrine,pulmonary, gastrointestinal (including severe gastroparesis),
cardiovascular, hepatic, psychiatric, neurologic, or clinically significant allergic
disease (excluding treated and untreated seasonal allergies at time of dosing).
Subjects who have chronic conditions other than T2DM (for example,
hypercholesterolemia or hypertension) but are controlled by either diet or stable (for
the last 4 weeks prior to screening) doses of medications may be included as well (for
example, a subject with hypercholesterolemia on appropriate treatment is eligible).

NCT01856595
Pfizer
Completed
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
NCT03519178
All Genders
18+
Years
Multiple Sites
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
NCT01945775
All Genders
18+
Years
Multiple Sites
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
A Phase 1, Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06291874 In Adults With Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Diabetes Mellitus, Type 2
  • Drug: PF-06291874
    The dosing schedule is 5, 15, 50 and 150 mg QD for 14 days for the first 4 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days. Doses for part A cohort 5 and Part B cohorts 2 and 3 are TBD QD for 28 days.
  • Drug: Placebo
    Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1-4 and Part B cohort 1) or 28 days (Part A cohort 5 and Part B cohorts 2 and 3).
  • Experimental: PF-06291874
    Intervention: Drug: PF-06291874
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
117
March 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and female subjects of non-childbearing potential between the ages of 18 and 70 years, inclusive of age at the time of the screening visit.

Female subjects of non-childbearing potential must meet at least one of the following criteria:

  1. Achieved postmenopausal status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum FSH level within the laboratory's reference range for postmenopausal females;
  2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
  3. Have medically confirmed ovarian failure.
  4. All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.

    • Body Mass Index (BMI) of 18.0 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).
    • An informed consent document signed and dated by the subject.
    • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

PART A ONLY: Subjects treated with metformin monotherapy for at least 3 months at the time of the screening visit; and have been on a stable dose of metformin for at least 6 weeks prior to the first dose of study drug on Day 1. Subjects must be taking a minimum total metformin daily dose of least 1000 mg. Subjects treated with a dipeptidyl peptidase-4 inhibitor (DPP-4i), a sulfonylurea or a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in combination with metformin may be eligible if washed off the DPP-4i, sulfonylurea or SGLT-2i for a minimum of 4 weeks prior to dosing. Subjects being washed off a DPP-4i, sulfonylurea or SGLT-2i will still need to meet the fasting glucose requirements as defined in the Inclusion Criteria.

PART B ONLY: Subjects treated with metformin plus a sulfonylurea for at least 3 months at the time of the screening visit; and have been on a stable dose of metformin and a sulfonylurea for at least 6 weeks prior to first dose of study drug on Day 1. Subjects must be taking a minimum total metformin daily dose of least 1000 mg and a total daily dose of sulfonylurea that is at least the minimum recommended starting dose found in the product label. Subjects treated with a DPP-4i or SGLT-2i in combination with metformin and a sulfonylurea may be eligible if washed off the DPP-4i or SGLT-2i for a minimum of 4 weeks before dosing.

Exclusion Criteria:

  • History of Type 1 diabetes mellitus or secondary forms of diabetes.
  • One or more self-reported hypoglycemic episodes of severe intensity within 3 months of screening; or two or more self-reported hypoglycemic episodes of severe intensity within the last 6 months.
  • Recent [ie, within six (6) months prior to screening] evidence or medical history of unstable concurrent disease such as: clinically significant hematological, endocrine,pulmonary, gastrointestinal (including severe gastroparesis), cardiovascular, hepatic, psychiatric, neurologic, or clinically significant allergic disease (excluding treated and untreated seasonal allergies at time of dosing). Subjects who have chronic conditions other than T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either diet or stable (for the last 4 weeks prior to screening) doses of medications may be included as well (for example, a subject with hypercholesterolemia on appropriate treatment is eligible).
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01856595
B4801003
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now